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Accumulation of oxalate leads to hyperoxaluria and calcium oxalate nephrolithiasis in man. Since oxalate 
is a metabolic end product in mammals, the feasibility of its enzymic degradation has been tested in vivo 
in rats by administering exogenous oxalate oxidase. Oxalate oxidase, isolated from banana fruit peels, in 
its native form was found to be non-active at the physiological pH of the recipient animal. However, its 
functional viability in the recipient animal was ensured by its prior binding with ethylenemaleic anhydride, 
thus shifting its pH activity curve towards the alkaline range. Rats implanted with dialysis membrane cap- 
sules containing such immobilized oxalate oxidase in their peritoneal cavities effectively metabolized intra- 
peritoneally injected [Yloxalate as well as its precursor [Wlglyoxalate. The implantation of capsules con- 
taining coentrapped multienzyme preparations of oxalate oxidase, catalase and peroxidase led to a further 
degradation of administered [Wloxalate in rats. 
Oxalate oxidase Nephrolithiasis 
1. INTRODUCTION 
In man, oxalate is a metabolic end product with 
no enzyme present to act on it [l]. Consequently, 
in conditions of its enhanced endogenous ynthesis 
or increased absorption from the diet, oxalate can 
accumulate and lead to hyperoxaluria [l-5]. 
Regardless of causes, the major clinical manifesta- 
tion of hyperoxaluria is calcium oxalate 
nephrolithiasis [ 11. A variety of therapeutic 
measures have been recommended for hyperox- 
aluric syndromes. Depending upon the specific 
pathophysiology, treatments have resorted to the 
restriction of dietary calcium and oxalate intake, 
use of oxalate-trapping agents, intake of larger 
volume of fluid and chemical inhibitors of oxalate 
precipitation and haemodialysis [1,2]. 
The manifestation of hyperoxaluria, in a wider 
sense, can be considered as a metabolic disorder 
resulting from the absence of an oxalate- 
decomposing enzyme. One of the newer ap- 
proaches of curing such metabolic diseases is the 
application of enzyme supplementation therapy 
Enzyme therapy Immobilized enzyme 
[6-S]. Though mammalian systems do not possess 
oxalate-degrading enzymes, oxalate oxidases 
capable of breaking down oxalate into CO2 and 
Hz02 are known to occur in the plant kingdom [ 11. 
We have therefore examined the attractive 
possibilities of employing enzyme therapy for 
degrading endogenous oxalate in hyperoxaluric 
conditions. As a prerequisite, we modified oxalate 
oxidase, isolated from banana fruit peels [9], by 
covalently binding it to a polyanionic electrolyte, 
ethylenemaleic anhydride (EMA), shifted its pH 
activity curve towards the alkaline range, and thus 
rendered it functional at the physiological pH of 
7.4 of the recipient animal. Here we report the 
feasibility of reducing the endogenous concentra- 
tion of oxalate in rats by implanting dialysis mem- 
brane capsules containing EMA-oxalate oxidase in 
their peritoneal cavities. 
2. MATERIALS AND METHODS 
[‘4C]Oxalic acid (spec. act. 8.8 mCi/mmol) and 
[l-14C]glyoxalic acid (spec. act. 7.33 mCi/mmol) 
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were obtained from Amersham. Oxalate decarbox- oxalate was determined after trapping it as describ- 
ylase was purchased from Sigma. Oxalate oxidase ed [4,5]. The activities of banana oxalate oxidase 
was isolated from banana fruit peels (Muss preparations were determined spectrophotomet- 
paradiasica cv. French plaintain) as described [9]. rically [9]. 
2.1. Covalent binding of oxalate oxidase to 
polyanionic electrolyte 
3. RESULTS 
The EMA derivative of banana oxalate oxidase 
was prepared according to Goldstein [lo]. About 
500 mg (wet wt) of banana oxalate oxidase 
preparation [9] (1.8 U/mg protein) was used for 
derivatisation. 1 U activity is defined as the 
amount of enzyme required to convert 1 pmol 
substrate to product in 1 min at pH 5.2. The 
recovery of enzyme activity in the EMA derivative 
ranged between 72 and 80%. In the case of mul- 
tienzyme derivatisation, a solution containing 
300 mg oxalate oxidase [9], 10 mg catalase (Sigma, 
2000 U/mg protein) and 100 mg peroxidase 
(Sigma type I) was used. 
2.2. Encapsulation of EMA-enzyme in dialysis 
membranes and their surgical implantation in 
. rats 
Dialysis tubing of 50 cm (flat width 10 mm, 
The pH profiles of oxalate oxidase and EMA- 
oxalate oxidase are shown in fig.1. The native ox- 
alate oxidase exhibited optimal activity at pH 5.2, 
the enzyme being non-active beyond pH 6.5. 
However, oxalate oxidase on derivatisation with 
EMA showed a marked shift in its pH activity 
curve, more towards the alkaline range. The extent 
of broadening of the pH activity and the amount 
of catalytic activity displayed at a specific pH by 
the enzyme depended upon the ionic molarity of 
the buffer employed. Thus, at an alkaline pH of 
7.5 with 0.01 M phosphate buffer, EMA-oxalate 
oxidase displayed 30% of its optimal activity. 
When the molarity of the phosphate buffer was 
raised to 0.1, 9-12070 of its optimal activity could 
be observed at the same pH. 
Fig.2 shows the rate at which the membrane- 
encapsulated EMA-oxalate oxidase could decom- 
molecular mass cut off value 14 kDa) was sterilised 
prior to use and filled with EMA-oxalate oxidase 
suspended in 01. M potassium phosphate buffer, 
pH 7.5. Several capsules (10 mm, 1 x 6 mm 
diameter) were prepared from this and each con- 
tained approx. 12 units enzyme. 
1 
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Male Wistar rats (180-200 g) were fasted for 
24 h prior to treatment, but had free access to 
water. Laparotomy was performed, under mild 
ether anesthesia, by making a 1.5 cm dorsal inci- 
sion. Enzyme capsules were inserted into the 
peritoneal cavity, one on either side, and incisions 
were sutured. Control animals received the same 
treatment except for the presence of bovine serum 
albumin instead of oxalate oxidase in the capsules. 
To individual rats, 2 h post-surgery, 2 pmol 
[U-14C]oxalate, [14C]glyoxalate or labelled glyco- 
late in saline was administered intraperitoneally. 
The treated animals were housed in metabolic 
cages for urine collection. 
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2.3. Analytical methods 
The amount of labelled oxalate present in the 
urine sample was determined using oxalate decar- 
boxylase. The 14C02 liberated from the labelled 
Fig.1. The DH profiles of native oxalate oxidase and 
EMA-oxalate oxidase at different buffer molarity. 
Buffers used: pH 5-6 (K~HPO~-HSPO~); pH 6.5-7.5 
(K2HP04-KH2P04). (m) Native oxalate oxidase; 
(+--o) EMA-oxalate oxidase activity with 0.01 M 
buffer; (o--u) EMA-oxalate oxidase activity with 
0.1 M buffer. 
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Rat, like man, cannot metabolize oxalate and 
therefore excretes major amounts of ingested, syn- 
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thesized or administered oxalate in its urine. 
However, rats when impl~ted with EMA-oxalate 
oxidase were able to decompose large amounts of 
injected [14C]oxalate (fig.3A). Thus, compared 
with controls, oxalate oxidase-treated animals con- 
sistently excreted lesser amounts of unmetabolized 
oxalate in 24 h urine following daily administra- 
tion of [*4C]oxalate, during a 15 day period of in- 
vestigation. While the control animals excreted as 
high as 64-76% of the injected oxalate, the 
enzyme-treated rats excreted merely 28-37% dur- 
ing the first 8 days post-implantation and 40-52% 
on subsequent days. 
Fig.2. The rate of degradation of oxalate in vitro by 
capsule containing EMA-oxalate oxidase. An enzyme 
capsule was placed in a 25 ml conical flask containing 
5 prnol oxalic acid in 10 ml of 0.1 M phosphate buffer 
(pH 7.5) and incubated in a shaker water bath at 37°C. 
Hz02 formed in the diaIysate was measured as described 
[91. 
pose oxalate, presented in an external medium hav- 
ing a pH of 7.5. For this purpose, the rate of for- 
mation of Hz02 in the dialysate was determined at 
different time intervals. After an initial lag of 
45-50 min, the oxalate oxidase activity was found 
to be essentially linear for 6 h, under the condi- 
tions employed. 
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Fig.3. The percent recovery of labelled oxalate in 24 h 
urine in control and enzyme-treated animals following 
daily injection of [1-r4C]oxalate. Panel A: (0) control 
rat; (0) EMA-oxalate oxidase-treated animals; panel B: 
(0) control rat; (e) multienzyme-treated rats. Each 
value is an average of 4 experiments. 
The implantation of multienzyme capsules con- 
taining EMA derivatives of oxalate oxidase, 
catalase and peroxidase resulted in a higher rate of 
metabolic degradation of administered [14C]ox- 
alate. Such multienzyme-treated rats excreted a 
meagre amount of 9-20% of the injected dose dur- 
ing the first 8 days post-implantation and on subse- 
quent days in the range 19-44% (fig.3B). Though 
a reduction in the functional performance of the 
implanted multienzyme capsule was observed in 
due course, the loss of enzyme activity was less 
marked when compared with the monoenzyme 
preparation. 
In mammals glyoxalate is the immediate major 
precursor of oxalate [2] whereas glycolate is shown 
to be both a direct as well as an intermediate 
precursor of oxalate via glyoxalate in in vitro ex- 
Table 1 
[‘*C]Oxalate recoveries in 24 h urine of multienzyme- 
implanted rats following intraperitoneal injection of 
precursors 
Compound injected Percent recovery of injected 
“C-compound as 
[‘4C]oxalate in 24 h urine 
Control Multienzyme- 
treated 
[I-‘*C]Glyoxalate 13.4 * 1.1 5.2 * o.4a 
[ l-‘4C]Glycolate 9.0 f 0.8 3.1 + 0.6a 
a P < 0.001, as compared with control 
Each value represents mean f SE of 4 animals 
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periments with human and rat livers [2,11]. The 
multienzyme-treated rats were able to degrade 
newly formed [14C]oxalate from the intraperi- 
toneally injected [14C]glyoxalate or [ 1 -14C] -
glycolate (table 1). 
4. DISCUSSION 
Most pathological conditions in man involving 
oxalic acid are associated with an increased urinary 
excretion of oxalate [l]. Oxalate once formed or 
absorbed cannot be metabolized further owing to 
the absence of an oxalate-metabolizing enzyme 
thus leading to hyperoxaluria. The idea of curing 
such metabolic disorders by administering the re- 
quired enzymes in immobilized form is gaining 
wider recognition. However, enzymes in their 
native forms are unsuitable for therapeutic studies 
in animals since they become inactivated, provoke 
immune reactions and fail to act at pH other than 
their own activity ranges [7,8,12]. Other factors 
that still restrict its practical applicability include 
(i) the cost of the enzyme, (ii) the isolation of the 
protein in large quantities and (iii) the non- 
availability of suitable animal models to evaluate 
the efficacy of enzyme therapy [7,13,14]. 
In this study, some of these have been overcome 
to a large extent. We have already developed an in- 
expensive and rapid procedure for the isolation of 
oxalate oxidase from banapa peels [9]. Rat, like 
man, is incapable of metabolizing oxalate and 
therefore serves as a good model for studies on 
disorders of oxalate metabolism. Though oxalate 
oxidase in the native form is non-active beyond pH 
6.5, we have rendered it suitable for therapeutic 
studies by binding it to the polyionic carrier EMA 
and extending its pH activity curve close to the 
physiological pH of the animal. Banana enzyme, 
in soluble as well as in EMA derivative form, elicits 
a specific immune response in rats, but failed to do 
so when implanted in animals after encapsulation 
in dialysis membranes, at least for a period of 30 
days (not shown), 
Our results demonstrate that the concentration 
of the endogenous oxalate could be effectively 
reduced in rats by implanting EMA-oxalate ox- 
idase capsules in the peritoneal cavity. The syn- 
thesis or ingestion of oxalate in hyperoxaluric con- 
ditions is a chronic process. Therefore, for the en- 
zyme therapy to be effective, it is essential that the 
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supplemented oxalate oxidase sustains its catalytic 
activity for longer duration. Thus, here the 
animals that were implanted with EMA-oxalate 
oxidase were able to degrade continuously [ 14C]ox- 
alate, administered aily for a period of 2 weeks 
though the functional performance of the im- 
planted enzyme tended to decline in due course. 
The inclusion of EMA derivatives of catalase 
and peroxidase along with oxalate oxidase in the 
capsules has a potentiating effect on the activity of 
oxalate oxidase in the rat. As a result, the multiple 
enzyme-treated rats excreted lesser amounts of ox- 
alate for a longer period in contrast to animals 
which received oxalate oxidase alone. These en- 
zyme preparations have also been found to be ef- 
fective in eliminating newly formed oxalate from 
administered precursors like glyoxalate and 
glycolate. 
Current techniques in enzyme therapy exploit a 
variety of novel supports such as semipermeable 
membranes, artificial red blood cells, collodion 
and liposomes for this purpose [6-S]. The binding 
of oxalate oxidase to EMA and subsequent encap- 
sulation in dialysis membranes offer several advan- 
tages. Such immobilized enzyme preparations are 
easy to handle, implant and also immunologically 
biocompatible. The encapsulated enzyme is also 
inaccessible to proteolytic enzymes and micro- 
organisms due to permeability barriers. In addi- 
tion, several enzymes could be easily encapsulated 
to carry out a series of metabolic reactions. 
The observed decline in the functional perfor- 
mance of oxalate oxidase in due course appears to 
be caused by the product H202. Such local poison- 
ing of immobilized glucose oxidase by Hz02 has 
been reported [ 151. Though Hz02 is the substrate 
for both catalase and peroxidase, these enzymes 
themselves are highly susceptible to local poisoning 
by H202. In this study, this effect has been 
minimized by simultaneously co-entrapping 
catalase and peroxidase along with oxalate oxidase 
in the polyionic carrier. 
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